文献速递产科母胎医学

早产前硫酸镁用于神经保护:更新的Cochrane系统综述

Magnesium Sulfate Before Preterm Birth for Neuroprotection: An Updated Cochrane Systematic Review.
PubMed 文献 · Obstet Gynecol · 2024-06-03

本系统综述纳入6项随机对照试验(5917名孕妇和6759名胎儿),评估硫酸镁用于早产儿神经保护的有效性和安全性。与安慰剂相比,硫酸镁降低了儿童至校正年龄2岁时脑性瘫痪的风险(RR 0.71,95% CI 0.57-0.89)和死亡或脑性瘫痪的风险(RR 0.87,95% CI 0.77-0.98),证据确定性高;但增加了严重到需要停止治疗的不良反应(RR 3.21,95% CI 1.88-5.48)。

要点

  • 早产前硫酸镁可降低儿童脑性瘫痪和死亡或脑性瘫痪风险,证据确定性高。
  • 硫酸镁对孕妇死亡或心脏呼吸骤停无显著影响,但增加需停药的不良反应。
  • 硫酸镁可降低严重新生儿脑室内出血风险,证据确定性中等。

核心结论

  • 早产前硫酸镁用于胎儿神经保护可降低儿童脑性瘫痪和死亡或脑性瘫痪的风险。

研究设计与样本

  • 系统综述与Meta分析,纳入6项随机对照试验,共5917名孕妇和6759名胎儿,随机分组时孕周小于34周。
  • 试验在高收入国家进行(美国2项,澳大利亚和新西兰2项,丹麦和法国各1项),开始于1995年至2018年间。
  • 两名作者评估纳入试验、提取数据并评价偏倚风险、可信度和证据确定性(GRADE)。

主要发现

  • 至校正年龄2岁,硫酸镁组与安慰剂组相比脑性瘫痪风险降低(RR 0.71,95% CI 0.57-0.89;6项RCT,6107名儿童),证据确定性高。
  • 至校正年龄2岁,硫酸镁组与安慰剂组相比死亡或脑性瘫痪风险降低(RR 0.87,95% CI 0.77-0.98;6项RCT,6481名儿童),证据确定性高。
  • 硫酸镁对至校正年龄2岁的死亡风险影响很小或没有影响(证据确定性中等),对学龄期这些结局影响很小或没有影响(证据确定性低)。
  • 硫酸镁对孕妇死亡或心脏呼吸骤停影响很小或没有影响(证据确定性低),但增加严重到需要停止治疗的不良反应(RR 3.21,95% CI 1.88-5.48;3项RCT,4736名参与者;证据确定性中等)。
  • 硫酸镁降低严重新生儿脑室内出血风险(证据确定性中等)。

局限性

  • 需要进一步研究儿童长期获益和危害、参与者和治疗特征对效应变异的影响,以及研究结果对中低收入国家的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically review the evidence for the effectiveness and safety of magnesium sulfate as a fetal neuroprotective agent when given to individuals at risk of preterm birth. DATA SOURCES: We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov , the World Health Organization International Clinical Trials Registry Platform (through March 17, 2023), and reference lists of relevant studies. METHODS OF STUDY SELECTION: Randomized controlled trials (RCTs) assessing magnesium sulfate for fetal neuroprotection in pregnant participants at risk of imminent preterm birth were eligible. Two authors assessed RCTs for inclusion, extracted data, and evaluated risk of bias, trustworthiness, and evidence certainty (GRADE [Grading of Recommendations Assessment, Development and Evaluation]). TABULATION, INTEGRATION, AND RESULTS: We included six RCTs (5,917 pregnant participants and 6,759 fetuses at less than 34 weeks of gestation at randomization). They were conducted in high-income countries (two in the United States, two across Australia and New Zealand, and one each in Denmark and France) and commenced between 1995 and 2018. Primary outcomes: up to 2 years of corrected age, magnesium sulfate compared with placebo reduced the risk of cerebral palsy (risk ratio [RR] 0.71, 95% CI, 0.57-0.89; six RCTs, 6,107 children) and death or cerebral palsy (RR 0.87, 95% CI, 0.77-0.98; six RCTs, 6,481 children) (high-certainty evidence). Magnesium sulfate had little or no effect on death up to 2 years of corrected age (moderate-certainty evidence) or these outcomes at school age (low-certainty evidence). Although there was little or no effect on death or cardiac or respiratory arrest for pregnant individuals (low-certainty evidence), magnesium sulfate increased adverse effects severe enough to stop treatment (RR 3.21, 95% CI, 1.88-5.48; three RCTs, 4,736 participants; moderate-certainty evidence). Secondary outcome: magnesium sulfate reduced the risk of severe neonatal intraventricular hemorrhage (moderate-certainty evidence). CONCLUSION: Magnesium sulfate for preterm fetal neuroprotection reduces cerebral palsy and death or cerebral palsy for children. Further research is required on longer-term benefits and harms for children, effect variation by participant and treatment characteristics, and the generalizability of findings to low- and middle-income countries. SYSTEMATIC REVIEW REGISTRATION: The review protocol was based on a standard Cochrane Pregnancy and Childbirth template and our previous Cochrane Systematic Review (doi: 10.1002/14651858.CD004661.pub3 ; published before the introduction of PROSPERO).

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shepherd ES, Goldsmith S, Doyle LW, et al. Magnesium Sulfate Before Preterm Birth for Neuroprotection: An Updated Cochrane Systematic Review. Obstet Gynecol. 2024. PMID: 38830233. doi:10.1097/AOG.0000000000005644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。